LGVN vs. CRDL, JSPR, OSTX, COYA, HLVX, MNOV, XFOR, IMUX, EDIT, and ABOS
Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Cardiol Therapeutics (CRDL), Jasper Therapeutics (JSPR), OS Therapies (OSTX), Coya Therapeutics (COYA), HilleVax (HLVX), MediciNova (MNOV), X4 Pharmaceuticals (XFOR), Immunic (IMUX), Editas Medicine (EDIT), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry.
Longeveron vs.
Longeveron (NASDAQ:LGVN) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.
10.0% of Longeveron shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 19.1% of Longeveron shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Cardiol Therapeutics has a net margin of 0.00% compared to Longeveron's net margin of -967.49%. Longeveron's return on equity of -142.43% beat Cardiol Therapeutics' return on equity.
Longeveron presently has a consensus price target of $8.67, suggesting a potential upside of 409.80%. Cardiol Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 623.14%. Given Cardiol Therapeutics' higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Longeveron.
In the previous week, Longeveron's average media sentiment score of 1.00 beat Cardiol Therapeutics' score of 0.00 indicating that Longeveron is being referred to more favorably in the media.
Longeveron has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
Cardiol Therapeutics received 8 more outperform votes than Longeveron when rated by MarketBeat users. However, 94.12% of users gave Longeveron an outperform vote while only 63.16% of users gave Cardiol Therapeutics an outperform vote.
Cardiol Therapeutics has lower revenue, but higher earnings than Longeveron. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Summary
Cardiol Therapeutics beats Longeveron on 8 of the 15 factors compared between the two stocks.
Get Longeveron News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longeveron Competitors List
Related Companies and Tools
This page (NASDAQ:LGVN) was last updated on 1/21/2025 by MarketBeat.com Staff
Free LGVN Stock Alerts